<p> Zydus Cadila is recalling over 14,800 bottles of Bromocriptine Mesylate capsules manufactured by Cadila Healthcare on account of out of specification results in the US market.<br /><br /></p>.<p>According to information available on the United States Food and Drug Administration (USFDA) site, Zydus Pharmaceuticals USA Inc is recalling drugs manufactured by the Ahmedabad-based Cadila Healthcare.<br /><br />14,808 bottles of Bromocriptine Mesylate Capsules USP, 5 mg are being recalled on account of "Out of specification results noticed in related substance test during analysis of 24 month long-term (25 degree Celsius /65 pc RH) stability samples of two batches," the latest enforcement report of the USFDA said.<br /><br />The ongoing voluntary US nation-wide recall is class II recall, it added.<br />As per the USFDA a class II recall is initiated in "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."</p>
<p> Zydus Cadila is recalling over 14,800 bottles of Bromocriptine Mesylate capsules manufactured by Cadila Healthcare on account of out of specification results in the US market.<br /><br /></p>.<p>According to information available on the United States Food and Drug Administration (USFDA) site, Zydus Pharmaceuticals USA Inc is recalling drugs manufactured by the Ahmedabad-based Cadila Healthcare.<br /><br />14,808 bottles of Bromocriptine Mesylate Capsules USP, 5 mg are being recalled on account of "Out of specification results noticed in related substance test during analysis of 24 month long-term (25 degree Celsius /65 pc RH) stability samples of two batches," the latest enforcement report of the USFDA said.<br /><br />The ongoing voluntary US nation-wide recall is class II recall, it added.<br />As per the USFDA a class II recall is initiated in "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."</p>